---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-045204"
form_type: "8-K"
ticker: "ROIV"
cik: "0001635088"
company_name: "Roivant Sciences Ltd."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:30:27.501006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Roivant accelerates key pipeline timelines; Immunovant raises $550M

## Summary
- Brepocitinib NDA filing in dermatomyositis expected early 2026; commercial launch early 2027.
- Phase 3 brepocitinib trial in non-infectious uveitis fully enrolled; topline data now H2 2026.
- Brepocitinib proof-of-concept in cutaneous sarcoidosis fully enrolled; topline data now H1 2026.
- IMVT-1402 potentially registrational trial in D2T RA topline data now expected CY 2026.
- Immunovant financing led by Roivant generated ~$550M gross proceeds, extending cash runway to IMVT-1402 launch in GD.

## SEC filing metadata
- accession: 0001140361-25-045204
- form_type: 8-K
- ticker: ROIV
- cik: 0001635088
- company_name: Roivant Sciences Ltd.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1635088/000114036125045204/0001140361-25-045204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1635088/000114036125045204/ef20061071_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-045204
- JSON: https://secwatch.observer/filing/0001140361-25-045204.json
- Plain text: https://secwatch.observer/filing/0001140361-25-045204.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.